Haemonetics Past Earnings Performance

Past criteria checks 5/6

Haemonetics has been growing earnings at an average annual rate of 13.7%, while the Medical Equipment industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 5.5% per year. Haemonetics's return on equity is 13.4%, and it has net margins of 10%.

Key information

13.7%

Earnings growth rate

13.8%

EPS growth rate

Medical Equipment Industry Growth8.9%
Revenue growth rate5.5%
Return on equity13.4%
Net Margin10.0%
Next Earnings Update09 May 2024

Recent past performance updates

The Strong Earnings Posted By Haemonetics (NYSE:HAE) Are A Good Indication Of The Strength Of The Business

Feb 15
The Strong Earnings Posted By Haemonetics (NYSE:HAE) Are A Good Indication Of The Strength Of The Business

Recent updates

Haemonetics Corporation's (NYSE:HAE) Share Price Matching Investor Opinion

Apr 12
Haemonetics Corporation's (NYSE:HAE) Share Price Matching Investor Opinion

Haemonetics Corporation (NYSE:HAE) Shares Could Be 35% Below Their Intrinsic Value Estimate

Mar 07
Haemonetics Corporation (NYSE:HAE) Shares Could Be 35% Below Their Intrinsic Value Estimate

Haemonetics Corporation: Improved Performance, Another Bolt-On Deal

Mar 06

The Strong Earnings Posted By Haemonetics (NYSE:HAE) Are A Good Indication Of The Strength Of The Business

Feb 15
The Strong Earnings Posted By Haemonetics (NYSE:HAE) Are A Good Indication Of The Strength Of The Business

The Price Is Right For Haemonetics Corporation (NYSE:HAE)

Jan 01
The Price Is Right For Haemonetics Corporation (NYSE:HAE)

Haemonetics: Solid Performance Of This Blood Play

Nov 22

Here's Why We Think Haemonetics (NYSE:HAE) Might Deserve Your Attention Today

Nov 14
Here's Why We Think Haemonetics (NYSE:HAE) Might Deserve Your Attention Today

Is Haemonetics (NYSE:HAE) A Risky Investment?

Oct 24
Is Haemonetics (NYSE:HAE) A Risky Investment?

Haemonetics Offers Relatively Rare Momentum In A Tough Medical Device Environment

Oct 13

Haemonetics' Fiscal Q1 2024: Blood, Sweat, And Stellar Gains

Aug 09

Here's Why Haemonetics (NYSE:HAE) Has Caught The Eye Of Investors

Aug 09
Here's Why Haemonetics (NYSE:HAE) Has Caught The Eye Of Investors

An Intrinsic Calculation For Haemonetics Corporation (NYSE:HAE) Suggests It's 48% Undervalued

Jul 25
An Intrinsic Calculation For Haemonetics Corporation (NYSE:HAE) Suggests It's 48% Undervalued

Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

Jul 07
Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

Apr 06
Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 46% Undervaluation?

Mar 19
Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 46% Undervaluation?

Haemonetics Executing Well, But Valuation Dogged By Concerns About A Large Customer

Feb 16

Haemonetics: Earnings Rate Of Change Justifies High Multiples

Feb 01

We Think Haemonetics (NYSE:HAE) Can Manage Its Debt With Ease

Jan 05
We Think Haemonetics (NYSE:HAE) Can Manage Its Debt With Ease

Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 36% Undervaluation?

Dec 15
Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 36% Undervaluation?

Haemonetics Q2 2023 Earnings Preview

Nov 04

Haemonetics (NYSE:HAE) Seems To Use Debt Rather Sparingly

Oct 04
Haemonetics (NYSE:HAE) Seems To Use Debt Rather Sparingly

Haemonetics: Plasma Thesis Continues To Play Out, Reiterate Buy

Sep 06

Haemonetics reaches new 52-week high; shares up 41% YTD

Aug 24

Haemonetics reports Q2 earnings beat; raises FY22 guidance

Aug 10

A Look At The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)

Aug 10
A Look At The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)

Here's Why Haemonetics (NYSE:HAE) Can Manage Its Debt Responsibly

Jul 03
Here's Why Haemonetics (NYSE:HAE) Can Manage Its Debt Responsibly

Haemonetics: Upside Case Hinges On Blood Plasma Collection Market

Jun 11

Calculating The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)

May 11
Calculating The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)

Is Haemonetics (NYSE:HAE) Using Too Much Debt?

Apr 01
Is Haemonetics (NYSE:HAE) Using Too Much Debt?

Calculating The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)

Jan 28
Calculating The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)

Is Haemonetics (NYSE:HAE) Using Too Much Debt?

Dec 20
Is Haemonetics (NYSE:HAE) Using Too Much Debt?

Is Haemonetics Corporation (NYSE:HAE) Worth US$68.5 Based On Its Intrinsic Value?

Oct 28
Is Haemonetics Corporation (NYSE:HAE) Worth US$68.5 Based On Its Intrinsic Value?

Haemonetics (NYSE:HAE) Is Doing The Right Things To Multiply Its Share Price

Oct 09
Haemonetics (NYSE:HAE) Is Doing The Right Things To Multiply Its Share Price

We Think Haemonetics (NYSE:HAE) Is Taking Some Risk With Its Debt

Sep 07
We Think Haemonetics (NYSE:HAE) Is Taking Some Risk With Its Debt

Revenue & Expenses Breakdown
Beta

How Haemonetics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NYSE:HAE Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Dec 231,27012740553
30 Sep 231,23912838253
01 Jul 231,21913737651
01 Apr 231,16911537449
31 Dec 221,1299637547
01 Oct 221,0848636044
02 Jul 221,0266833444
02 Apr 229934333246
01 Jan 229532329643
02 Oct 219343128241
03 Jul 219036427937
03 Apr 218707926432
26 Dec 2088410822931
26 Sep 2090310624130
27 Jun 209469625630
28 Mar 209887726630
28 Dec 199998029329
28 Sep 199886829631
29 Jun 199774929433
30 Mar 199685526235
29 Dec 189524630038
29 Sep 189392131741
30 Jun 189222331640
31 Mar 189044627835
30 Dec 17898-1730937
30 Sep 17892428333
01 Jul 17887428034
01 Apr 17886-2630238
31 Dec 169001630639
01 Oct 16906-5931442
02 Jul 16905-6631745
02 Apr 16909-5631745
26 Dec 15893-5031951
26 Sep 158912632251
27 Jun 158992033250
28 Mar 159101733754
27 Dec 149253034851
27 Sep 149353039654
28 Jun 149433938258
29 Mar 149393536654
28 Dec 139473832854
28 Sep 139533128450
29 Jun 139352129546

Quality Earnings: HAE has high quality earnings.

Growing Profit Margin: HAE's current net profit margins (10%) are higher than last year (8.5%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: HAE's earnings have grown by 13.7% per year over the past 5 years.

Accelerating Growth: HAE's earnings growth over the past year (32.3%) exceeds its 5-year average (13.7% per year).

Earnings vs Industry: HAE earnings growth over the past year (32.3%) exceeded the Medical Equipment industry 3.3%.


Return on Equity

High ROE: HAE's Return on Equity (13.4%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.